A patent review of mTOR inhibitors for cancer therapy (2011-2020)

Related Experiment Video

Updated: Nov 2, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Han-Yue Qiu1, Peng-Fei Wang1, Min Zhang1

  • 1Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, People's Republic of China.

Expert Opinion on Therapeutic Patents
|June 8, 2021
PubMed
Abstract

Insights

The mammalian target of rapamycin (mTOR) pathway is crucial in cancer, driving the development of mTOR inhibitors (mTORi). Further research and new technologies are needed to overcome challenges like side effects and drug resistance for effective cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) kinase is a key regulator in the PI3K/Akt/mTOR pathway, vital for tumor growth.
  • mTOR is a significant therapeutic target in oncology due to its central role in cancer biology.
  • Significant advancements in mTOR inhibitor (mTORi) development have occurred, including third-generation agents.

Purpose of the Study:

  • To review the progress of mTOR inhibitor development for anticancer applications.
  • To analyze patent literature from 2011-2020 concerning mTOR inhibitors.
  • To highlight challenges and future directions in mTORi-based cancer therapy.

Main Methods:

  • Review of patent literature focusing on mTOR inhibitors.
  • Analysis of developments in mTORi research between 2011 and 2020.
  • Synthesis of information on therapeutic potential and challenges.

Main Results:

  • The field of mTOR inhibitor development has seen considerable progress, with new agents emerging.
  • Patent literature reflects ongoing innovation in mTOR inhibitor design and application.
  • Challenges remain in achieving significant clinical success with current mTOR inhibitors.

Conclusions:

  • The complex regulatory network of mTOR presents challenges for developing clinically effective inhibitors.
  • Continued biological and medicinal chemistry research is essential for improving mTOR inhibitors.
  • New technologies for patient pre-diagnosis are crucial for personalized cancer treatment with mTOR inhibitors.
  • Development of novel mTOR agents is necessary to address side effects and drug resistance.
Keywords:
ATP-competitivecancer treatmentmTOR/PI3K dualmtor inhibitorsrapalinkrapalogs

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
16.1K